OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Delayed Börse Stuttgart 09:14:47 30/04/2024 BST | ||
| 7.76 EUR | -1.15% |
|
| Current month | +23.37% | ||
| 1 month | +23.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 7.76 | -1.15% | 0 |
| 29/04/24 | 7.85 | +1.29% | 0 |
| 26/04/24 | 7.75 | +1.31% | 0 |
| 25/04/24 | 7.65 | +11.35% | 0 |
| 24/04/24 | 6.87 | +0.88% | 0 |
Delayed Quote Börse Stuttgart
Last update April 30, 2024 at 09:14 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | CU2ATY |
| ISIN | DE000CU2ATY7 |
| Date issued | 17/04/2019 |
| Strike | 5,397 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.13 € |
|---|---|
| Lowest since issue | 1.01 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.1
USD
Average target price
164.3
USD
Spread / Average Target
+8.74%
- Stock Market
- Certificates
- Certificat
